Abstract:The term epigenetics encompasses all the modifications that are stable across cell generations, but which do not imply any change in DNA sequence. Post-translational modifications of the histones and DNA methylation are the most studied types of epigenetic information due to their major impact on transcription.Epigenetic deregulations may play a critical role in the tumorigenesis. Recent studies have demonstrated that the histone modification is important epigenetic mechanisms of gene regulation and plays essential roles both independently and cooperatively in tumor initiation and progression. Imbalance in histone acetylation can lead to transcriptional dysregulation of genes that are involved in the control of proliferation, cell-cycle progression, differentiation and apoptosis. Histone acetyltransferases (HATs) and histone deacetylases (HDACs) are two classes of enzymes regulating histone acetylation and whose altered activities have been identified in several cancers. HATs and HDACs determine the acetylation status of histones. This acetylation affects the regulation of gene expression, and inhibitors of HDACs have been found to cause growth arrest, differentiation and apoptosis of many tumours cells by altering the transcription of a small number of genes.The current research raises the possibility that histone deacetylase inhibitors (HDAIs) may prove potent effective in the treatment of cancers. HDAIs could enhance the therapeutic window for clinical applications and open up a highly specific new option for cancer treatment. In this review, we examine the current literatures on epigenetic changes in cancer and discuss the clinical potential of histone deacetylase inhibitors for treatment of cancer.

The emerging roles of HDACs and their therapeutic implications in cancer

The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy

Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications.

Exploring the role of histone deacetylase inhibitors in cancer development and therapeutic potential

Characterization of Histone Deacetylase Mechanisms in Cancer Development

Role of Histone Acetylation Modification in Posttranscriptional Gene Expression

The Structure and Function of Histone Deacetylases: the Target for Anti-cancer Therapy

Targeting histone deacetylases for cancer therapy: Trends and challenges

Targeting histone deacetylases: Emerging applications beyond cancer

New Development of HDAC Inhibitors As Anti-Cancer Agents

An Overview of HDAC Inhibitors and Their Synthetic Routes.

Histone Deacetylases in Modulating Cardiac Disease and Their Clinical Translational and Therapeutic Implications

Competitive or noncompetitive, that's the question: research toward histone deacetylase inhibitors

Histone deacetylases and cancer: causes and therapies

Histone Deacetylases (HDACs) Roles in Inflammation-mediated Diseases; Current Knowledge

HDAC11: A novel target for improved cancer therapy

Targeting the acetylation signaling pathway in cancer therapy

The role of protein acetylation in carcinogenesis and targeted drug discovery

Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy

Technologies of Targeting Histone Deacetylase in Drug Discovery: Current Progress and Emerging Prospects.

Research advances in the use of histone deacetylase inhibitors for epigenetic targeting of cancer.